Key Takeaways FOLD reported Q4 EPS of 10 cents, missing estimates, as revenues rose 24% Y/Y to $185.2M.Amicus saw Galafold sales rise 14% and Pombiliti plus Opfolda jump 51% Y/Y at constant exchange rates.BioMarin will acquire Amicus for $14.50 per share in a $4.8B cash deal set to close in Q2 2026.Amicus Therapeutics (FOLD) reported adjusted earnings of 10 cents per share for the fourth quarter of 2025, which missed the Zacks Consensus Estimate of 13 cents. The company had reported adjusted earnings of 9 c ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33497 Amicus Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 71-0869350 (State or Other Jurisdicti ...

Exhibit 99.1 Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates 2025 Total Revenue of $634M, up 17% Year-over-Year at CER Cash Position of $294M, a $44M Increase in 2025 Proposed Acquisition by BioMarin Expected to Close in Q2 2026, Subject to Closing Conditions PRINCETON, NJ, Feb. 20, 2026 – Amicus Therapeutics (Nasdaq: FOLD), a leading, global biotechnology company with a clear and compelling mission to develop and deliver transformative medicines for people living with r ...

2025 Total Revenue of $634M, up 17% Year-over-Year at CER Cash Position of $294M, a $44M Increase in 2025 Proposed Acquisition by BioMarin Expected to Close in Q2 2026, Subject to Closing Conditions PRINCETON, N.J., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a leading, global biotechnology company with a clear and compelling mission to develop and deliver transformative medicines for people living with rare diseases, today announced financial results for the full year ended Decemb ...

Amicus Therapeutics Inc. (NASDAQ:FOLD) is one of the 13 hot stocks to buy with the highest upside potential. On January 27, TD Cowen analyst Ritu Baral maintained the firm’s Hold rating on Amicus Therapeutics Inc. (NASDAQ:FOLD), as well as the $14.50 price target on the stock. Amicus’s pre-announced fourth-quarter and full-year 2025 total product revenue were modestly above expectations, according to TD Cowen, with Fabry disease medication Galafold delivering a clear outperformance versus consensus estimate ...

Industry Overview - The fourth-quarter 2025 reporting season for the Medical sector is nearing its final stretch, with only a few pharma and biotech companies left to report [1] - As of February 11, 73.3% of companies in the Medical sector, representing 91% of the sector's market capitalization, reported quarterly earnings, with 86.4% exceeding both earnings and sales estimates [2][10] - Overall, fourth-quarter earnings in the medical sector are expected to decrease by 0.6%, while sales are projected to rise by 10.4% compared to the previous year [4] Company Performance Johnson & Johnson - Reported strong fourth-quarter results, beating estimates for both earnings and sales [3] Novartis - Beat earnings estimates but faced revenue pressure due to generic competition for key drugs like Entresto and Promacta [3] Bristol Myers Squibb - Beat both earnings and sales estimates and issued encouraging guidance [3] Gilead Sciences - Earnings exceeded both top and bottom lines, supported by higher sales of HIV and Liver Diseases drugs [3] Bausch Health - Mixed performance with two earnings beats and two misses in the last four quarters, delivering a four-quarter average negative surprise of 6.26% [5] - Scheduled to report on February 18, with an Earnings ESP of -8.84% and a Zacks Rank 3 [7] Amicus Therapeutics - Disappointing earnings track record with three misses and one beat in the last four quarters, averaging a negative surprise of 20.21% [8] - Set to be acquired by BioMarin, with its lead drug Galafold showing solid uptake [9] BioMarin Pharmaceutical - Impressive track record, beating earnings estimates in each of the last four quarters with an average surprise of 66.51% [11] - Scheduled to report with an Earnings ESP of -3.23% and a Zacks Rank 3, driven by strong demand for its dwarfism drug Voxzogo [12] Insmed - Poor earnings track record with four consecutive misses, averaging a negative surprise of 20.64% [13] - Scheduled to report on February 19, with an Earnings ESP of +7.01% and a Zacks Rank 3 [14] - Lead drug Arikayce gaining traction, with a new drug approval marking a significant milestone [15] Madrigal Pharmaceuticals - Missed earnings expectations in three of the last four quarters, with an average negative surprise of 17.17% [16] - Scheduled to report on February 19, with an Earnings ESP of -852.37% and a Zacks Rank 4 [16][17]

Core Viewpoint - Investors are expected to focus on Amicus Therapeutics' sales performance and updates regarding its merger with BioMarin Pharmaceutical during the upcoming earnings report for Q4 and full-year 2025 [1][6]. Sales Performance - The Zacks Consensus Estimate for Q4 sales is $179.9 million, with earnings expected at 13 cents per share [1]. - Galafold sales are projected to be a key revenue driver, with estimates for Q4 sales at $157 million, reflecting strong demand and compliance [8]. - The combination therapy Pombiliti + Opfolda is also expected to contribute positively to revenues, following its FDA approval in September 2023 [7][8]. Earnings Estimates - The Zacks Consensus Estimate for 2025 EPS is stable at 35 cents, while the estimate for 2026 is 65 cents [2]. - The earnings surprise history shows Amicus has beaten earnings expectations only once in the last four quarters, with an average negative surprise of 20.21% [4]. Merger Details - BioMarin has agreed to acquire Amicus for $14.50 per share, totaling $4.8 billion, with the deal expected to close in Q2 2026 [9][10]. - Post-acquisition, BioMarin will add Galafold and Pombiliti to its portfolio and gain exclusive U.S. rights to the late-stage drug DMX-200 [10]. Stock Performance - Amicus shares have increased by 104.9% over the past six months, outperforming the industry growth of 23.8% [11]. - The stock is currently trading at a price-to-sales (P/S) ratio of 7.42, which is higher than the industry average of 2.46, but below its five-year mean of 8.72 [14][15]. Investment Outlook - The acquisition by BioMarin is seen as a potential catalyst for value realization beyond organic sales growth, with optimism surrounding the strong sales of marketed products [16]. - Despite concerns regarding competition and reliance on Galafold, the company is expected to maintain growth potential, making it advisable for current investors to hold their positions [17][19].

PRINCETON, N.J., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the presentation of new data from clinical and real-world studies of Galafold® (migalastat) in Fabry disease and POMBILITI® + OPFOLDA® (cipaglucosidase alfa plus miglustat) in late-onset Pompe disease. Data are being presented at the 22nd Annual WORLDSymposium™ 2026. “Amicus continues to advance the science and understanding of both Fabry and Pompe diseases, and we are proud to showcase new data for our me ...

Core Insights - Amicus Therapeutics, Inc. (NASDAQ:FOLD) is recognized as one of the best biotech stocks under $20, primarily due to its innovative treatments for rare diseases [1] - Jefferies downgraded FOLD from Hold to Buy and reduced the price target from $16 to $14.50, reflecting a cautious outlook despite takeover interest [1][2] - BioMarin announced plans to acquire Amicus Therapeutics for $14.50 per share, valuing the company at approximately $4.8 billion, which includes two marketed therapies generating significant revenue [2] Company Overview - Amicus Therapeutics focuses on developing and commercializing treatments for rare and orphan diseases, with a pipeline that includes therapies for genetic and metabolic disorders such as Fabry disease [3] - The company leverages precision science and patient-centric solutions to enhance long-term health outcomes for patients [3] Financial Performance - The combined revenue from Amicus's marketed therapies, Galafold and Pombiliti + Opfolda, reached $599 million over the past four quarters, indicating strong market performance [2]

Core Insights - Three stocks in the health care sector are signaling potential warnings for momentum-focused investors as of February 2, 2026 [1] Group 1: Momentum Indicators - The Relative Strength Index (RSI) is a key momentum indicator that compares a stock's performance on days with price increases to days with price decreases, helping traders gauge short-term performance [2] - A stock is generally considered overbought when its RSI exceeds 70, indicating potential caution for investors [2] Group 2: Specific Stocks - Brookdale Senior Living Inc (NYSE:BKD) and Mirum Pharmaceuticals Inc (NASDAQ:MIRM) are highlighted as major overbought stocks in the health care sector [3] - Amicus Therapeutics has seen a significant stock increase of approximately 139% over the past six months, with a 52-week high of $14.38 and an RSI value of 80.4, indicating it is overbought [3] - On the last trading day, Amicus Therapeutics' shares closed at $14.29, reflecting a slight gain of 0.1% [3]